BioChem and XTL Biopharmaceuticals to Collaborate in Hepatitis Drug Discovery.REHOVOT, Israel and LAVAL, QUEBEC, Canada--(BUSINESS WIRE)-- Aug. 9, 1995--XTL Biopharmaceuticals Ltd. (private, formerly Xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, Technologies, Ltd.) and BioChem Therapeutic Inc., a wholly-owned subsidiary of BioChem Pharma Inc., today announced that they have signed an option agreement that could lead to an alliance for the discovery of novel drugs for the treatment of hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. infections and other viral infections. The primary focus of the collaborative program is the identification of novel anti-hepatitis lead compounds and drug candidates employing BioChem's expertise in medicinal chemistry and XTL XTL Crystal XTL Xpress Train Limited XTL Anything-To-Liquids (synthetic fuels) XTL XML Template Language XTL Xml Transformation Language XTL Extensible Transformation Language XTL Executable Temporal Language Biopharmaceutical's proprietary animal modeling system for hepatitis viral infections. Under the terms of the agreement, XTL will work exclusively with BioChem on rodent models for hepatitis during a six month option period. Upon attainment of certain technical goals by XTL, BioChem will enter into an alliance with XTL to develop small molecule anti-virals. "We believe that BioChem is the ideal partner for XTL in advancing and utilizing our hepatitis modeling capabilities. BioChem has already shown its strong medicinal chemistry capabilities in discovering 3TC(TM) for the treatment of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. infection and lamivudine for the treatment of chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis B infection. We hope that the synergy that could be created in a research alliance will lead to further successes in developing drugs for hepatitis C," said Martin Becker, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of XTL Biopharmaceuticals, Ltd. "BioChem is fully committed to the discovery of novel antivirals and hepatitis C infection is an important medical need which is currently underserved. XTL brings to this collaboration strong science and innovative disease models. We believe that this collaboration should produce promising new medicines," said Michael Grey, President of BioChem Therapeutic Inc. BioChem Pharma is an international biopharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. The Company's shares are traded on the Montreal and Toronto Stock exchanges (BCH BCH Beach BCH Banco Central de Honduras BCH Boot Console Handler BCH Boulder Community Hospital (Boulder, CO, USA) BCH Broadcast Channel BCH Belfast City Hospital BCH Banco Central-Hispano ) and on NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on (BCHXF). XTL Biopharmaceuticals Ltd., an early stage private biopharmaceutical company located in Rehovot, Israel, was founded on a radiation chimera technology derived from the Weizmann Institute of Science The Weizmann Institute of Science (מכון ויצמן למדע) is a world-renowned institute of higher learning and research in Rehovot, Israel. . This technology allows for the development of fully human monoclonal antibodies as well as providing a tool for modeling of human diseases. XTL has developed models for hepatitis B and C infection in rodents which can be used to test potential anti-viral agents for these diseases. XTL is focused on autoimmune, viral and oncological diseases. CONTACT: BioChem Pharma: Christine Lennon Director, Investor Relations BioChem Pharma, Inc. 514/978-7771 or XTL Biopharmaceuticals: Dr. Martin Becker President and CEO XTL Biopharmaceuticals, Ltd. 011/972-8-405134 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion